In This Issue, Volume 7, Issue 8

ACS Chem. Neurosci., 2016, 7 (8), pp 1025–1025 DOI: 10.1021/acschemneuro.6b00223 Publication Date (Web): August 17, 2016 Copyright © 2016 American Chemical Society Repurposing an Anticancer Drug to Target Alzheimer’s Disease Sunitinib is a well-established anticancer drug approved by the United States Food and Drug Administration. Now, Huang et al. (DOI: 10.1021/acschemneuro.5b00329) explore the effects of sunitinib on acetylcholinesterase (AChE) and memory-related task performance in mice associated with Alzheimer’s disease (AD). The authors show that sunitinib effectively inhibits AChE at submicromolar concentrations and that the drug might interact with both catalytic anion and peripheral anionic sites within AChE. The authors go on to show that sunitinib reverses cognitive impairments to a similar extent as donepezil, a marketed AChE inhibitor used for the treatment of AD. Given the clinical use of AChE…

Link to Full Article: In This Issue, Volume 7, Issue 8

Pin It on Pinterest

Share This